Primer set, kit and method for detecting monogenic diabetes related genes
A diabetes, single-gene technology, applied in the field of primer sets, can solve the problems of limited clinical application and high testing costs.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0090] The present embodiment is used to illustrate the method for detecting the pathogenic gene of single-gene diabetes mellitus using the primer combination of the present invention, and the specific steps are as follows:
[0091] Step A: Sample
[0092] For blood samples, saliva or other tissue samples obtained from hospitals or other research institutions, use a DNA extraction kit to extract whole genome DNA, and use a nucleic acid quantifier to measure the concentration of the extracted DNA. The DNA concentration is 50ng / ul, and the total amount is not. Below 200ng.
[0093] For the above samples, configure the PCR reaction system, for LMNA, PPP1R15B, KLF11, DCAF17, NEUROD1, PPARG, APPL1, WFS1, TRMT10A, CISD2, PIK3R1, ZFP57, RFX6, ZBTB2, GCK, PAX4, BLK, GATA4, CEL, PCBD1, SLC29A3, INS, ABCC8, KCNJ11, PAX6, HNF1A, PDX1, DNAJC3, PLIN1, HNF1B, GATA6, INSR, DYRK1B, AKT2, POLD1, HNF4A and MTTL1. For amplification, MJ1909CL37 Panel Mix A and MJ1909CL37 Panel Mix B were used ...
Embodiment 2
[0167] In order to verify the stability of the system and the accuracy of the typing results, we extracted DNA from blood samples from 6 random diabetic patients using the commonly used and recognized Agilent exome sequencing kits and the genes described in this patent, respectively. The detection kits were used for library construction and sequencing, and then for mutation site detection and analysis. The final result shows that the genotype of the target region obtained by this kit is exactly the same as the genotype of this region in the Agilent exome sequencing kit. It shows that the accuracy of this method for this region is comparable to that of Agilent and other whole-exome sequencing. Only the detected mutation sites are shown below.
[0168] Sample 1:
[0169]
[0170] Sample 2:
[0171]
[0172]
[0173] Sample 3:
[0174]
[0175]
[0176] Sample 4:
[0177] Sample 5:
[0178] Sample 6:
[0179]
[0180]
Embodiment 3
[0182] In order to verify the repeatability of the system, we carried out two repetitions of blood samples from 10 different diabetic patients. The final analysis results showed that the mutation sites found in the two experiments were exactly the same. Only the detected mutation sites are shown below.
[0183] Sample 1:
[0184]
[0185]
[0186] Sample 2:
[0187]
[0188]
[0189] Sample 3:
[0190]
[0191]
[0192] Sample 4:
[0193]
[0194]
[0195] Sample 5:
[0196]
[0197]
[0198] Sample 6:
[0199]
[0200]
[0201] Sample 7:
[0202]
[0203]
[0204]
[0205] Sample 8:
[0206]
[0207]
[0208] Sample 9:
[0209]
[0210]
[0211] Sample 10:
[0212]
[0213]
[0214] It is illustrated that the detection method provided by the present invention has good detection balance, high sensitivity, good repeatability and accurate typing results, and can be used as an auxiliary diagnostic tool for mon...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


